This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
